HOW NEXOPAMIL RACEMATE CAN SAVE YOU TIME, STRESS, AND MONEY.

MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre examine To judge many intravenous doses of sifalimumab, in Grownup individuals with dermatomyositis or polymyositis (NCT00533091). Key demo aims were to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, a